Darzi Takes Witty's Seat At UK Innovation Group, As Brexit Heats Up And NHS Adds Ambiguity
The UK's Accelerated Access Collaborative (AAC) has filled the hole left by ex-Glaxo CEO Andrew Witty's recent departure with public-sector stalwart Lord Ara Darzi. This should restore some certainty to the initiative when the UK health-care sector was thrown into confusion by the promise of £20bn more NHS funding and by ongoing Brexit machinations with uncertain impact.
You may also be interested in...
Digital tools and maximizing the data derived from them will influence the delivery of health care in ways and to extents yet unknown. Andrew Davies, market access director for UK industry group ABHI, explains the industry's planning around this, and calls for a rethink on innovation market access structures, which are still failing to meet industry's needs.
During the week of the ostensibly pivotal EU Summit on Brexit, the UK government has made the EU27 wait for its white paper on proposed post-EU trading arrangements. The UK medtech industry, in turn, is kept waiting on its EU future. But far from remaining idle, manufacturers are focusing on innovation adoption and working with the NHS, where there is a new sense of purpose, and maybe a light at the end of the tunnel.
Diagnostics should be funded in a way that recognizes the value they bring. The UK IVD industry should also have a seat on the newly-formed Life Sciences Council. These are just two changes that would help diagnostics break through the adoption barrier in the UK and help the health-care system save "billions," say manufacturers.